United States Patent 4,876,248: Scope, Claim Map, and US Landscape
US Drug Patent 4,876,248 claims a chemical entity class and tied pharmaceutical formulations built around methylene-diphosphonic (methylene-disphosphonic) acids (and their base salts). The patent scope is defined by (i) a core methylene-linked diphosphonate scaffold, (ii) substitution constraints on three variables (R1, R2, R3, n), and (iii) multiple explicit carve-outs for a specific R2 pattern when n=0.
What is claimed, at the chemical and legal level?
Claim 1: Core compound genus with defined substitution limits
Claim 1 is a methylene-diphosphonic acid compound with a structure defined by a formula (not reproducible in text from the image placeholders) and these parameter constraints:
- R1: hydrogen or straight/branched lower alkyl with 1 to 4 carbon atoms
- R2: phenyl ring that is optionally substituted one or more times by one or more of:
- halogen
- nitro (NO2)
- lower alkyl
- lower alkoxy
- trifluoromethyl (CF3)
- amino (NH2)
- carboxylic acid (COOH)
- R3: hydrogen or hydroxyl (OH)
- n: integer 0 to 10
- Proviso 1 (n vs R3): n cannot be 0 if R3 is OH
- Proviso 2 (explicit R2 exclusion when n=0 with specific R1/R3 settings):
- R2 must be different from a defined group of the form shown in the patent (placeholder ##STR57##) where:
- Q is halogen, nitro, or trifluoromethyl
- T is methyl, ethyl, or butyl
- This exclusion applies when:
- R1 is methyl or ethyl
- R3 is hydrogen
- n = 0
- Salt coverage: inorganic or organic base salts are included when R1 = H.
Net effect: Claim 1 is a genus with broad latitude on the aromatic substitution pattern (R2) but with an explicit carve-out for a narrow scenario at n=0 plus R1 methyl/ethyl and R3 = H.
Claim 2: Narrower sub-genus (n=0) plus explicit sub-structure
Claim 2 depends on Claim 1 and narrows to:
- n = 0
- a particular sub-structure for the methylene-disphosphonic acid skeleton (placeholder ##STR58##)
- R3 = H
- and salts with bases when R1 = H
Claim 2 is an explicit subset of Claim 1 intended to lock in protection for the n=0 family with R3=H, without relying solely on the broader genus.
Claim 3: Alternative structure expression + salts
Claim 3 depends on Claim 1 and covers:
- a different formula representation (placeholder ##STR59##) or its base salts
The claim language indicates another sub-genus or an alternative depiction of the methylene-diphosphonic acid structure family.
Claim 4: Pharmaceutical composition with active-ingredient genus
Claim 4 claims pharmaceutical compositions containing:
- an effective amount of a compound of formula (I) (same variable definitions as Claim 1)
- or a base salt when R1=H
- in association with a pharmaceutically acceptable carrier
This claim is broad on formulation type and carrier selection; it is tied only to using an active ingredient that falls within the Claim 1 genus (or the associated sub-genus limitations built into formula (I)).
Claim 5: Dosage range
Claim 5 depends on Claim 4 and specifies the composition contains:
- 10 to 500 mg of the compound (formula I) as active ingredient.
This is a dose-amount limitation; it narrows the composition claim to compositions made or used with that active content per the relevant unit definition used by the patent.
How is claim scope structured around variables R1, R2, R3, and n?
Variable-by-variable scope
Below is the scope that determines whether an accused compound falls “inside” the claims.
| Variable |
Allowed values |
Legal impact on coverage |
| R1 |
H or lower alkyl C1–C4 |
Defines whether salts are available (salts included when R1=H) and triggers a specific exclusion when R1=methyl or ethyl (at n=0, R3=H). |
| R2 |
phenyl optionally substituted by: halogen, NO2, lower alkyl, lower alkoxy, CF3, NH2, COOH |
Broad aromatic substitution coverage. Includes many medicinal chemistry “handles.” |
| R3 |
H or OH |
Couples to n: if R3=OH then n cannot be 0. |
| n |
0–10 |
Controls chain length/positioning in the scaffold. A major carve-out is tied to n=0. |
Carve-out logic: the only explicit exclusion
The claim’s only explicit “negative” restriction is:
- When n=0, R1 is methyl or ethyl, and R3=H, then the compound cannot have an R2 equal to a specifically defined “group with formula ##STR57##” (Q and T constrained to halogen/NO2/CF3 and methyl/ethyl/butyl respectively).
This carve-out makes the claim a classic “genus with an exception,” which is often where landscape questions concentrate: design-arounds typically target the exception boundary.
What does this mean for infringement and design-around?
Infringement posture by claim level
- Claim 1 creates broad coverage for methylene-diphosphonic acid compounds that meet the R1/R2/R3/n constraints and do not hit the carve-out exception.
- Claims 2 and 3 add tighter coverage to particular sub-areas.
- Claim 4 extends coverage to pharmaceutical compositions, which can be easier to assert if a product includes any covered active ingredient.
- Claim 5 narrows to compositions with 10–500 mg active per unit definition.
Design-around vectors
Because R2 substitution is broadly allowed but only one exception is stated, practical avoidance focuses on:
-
Hit the exception exactly (when attempting to stay outside Claim 1, the exclusion condition is the clearest target):
- enforce n=0
- enforce R3=H
- select R1 = methyl or ethyl
- set R2 to match the excluded pattern with:
- Q in {halogen, nitro, CF3}
- T in {methyl, ethyl, butyl}
-
Avoid n=0 when R3=OH:
- Claim 1 forbids n=0 when R3=OH. Selecting R3=OH effectively restricts you to n=1–10.
-
Use salts carefully:
- salts of said compounds are claimed when R1 = H. If a product uses a different R1 form, the “salts included” language may not map directly to the claimed salt category.
What is the patent landscape risk around US 4,876,248?
Landscape framing based on claim architecture
Even without external file-wrapper prosecution details in the prompt, the claim architecture itself signals where risk clusters:
- Broad genus coverage (Claim 1) with many possible R2 substitutions is likely to create:
- dense “near-by” chemical variants that may still fall in the same genus
- significant citation overlap in chemical space (other methylene diphosphonate/methylene-disphosphonate analogs)
- A specific exception at n=0 indicates the applicant likely carved out one or more close prior-art or co-invented structures.
- Sub-genus locks (Claims 2 and 3) suggest additional protection for the most commercially or pharmacologically relevant members.
What to look for in the US landscape (actionable diligence points)
To map whether US 4,876,248 blocks a given development program, diligence should focus on:
- Whether competitor actives fall within the genus parameters:
- R1 in {H, C1–C4 alkyl}
- R2 substituted phenyl includes common substituents listed in Claim 1
- n in 0–10 and R3 in {H, OH} with the n/R3 interaction
- Whether competitor hits the exception boundary:
- n=0 with R1 methyl/ethyl and R3=H while R2 matches the excluded pattern
- Whether competitor formulations fall within dosage:
- for composition infringement risk, check whether product tablets/capsules correspond to the patent’s 10–500 mg active ingredient range per defined unit.
Claim-set consolidation: what is “protected” in practice?
A practical claim map
- Active ingredient protection (core): Claim 1 (plus Claims 2 and 3)
- Product protection (composition): Claim 4
- Unit dosage protection: Claim 5
This pattern is typical of patents that target:
- the underlying chemical entity class
- then wrap that into pharmaceutical product claims for leverage against branded and generic products
Key Takeaways
- US 4,876,248 claim 1 is a broad genus of methylene-diphosphonic acid compounds defined by R1 (H or C1–C4 alkyl), R2 (substituted phenyl by a wide set of groups), R3 (H or OH), and n (0–10).
- Coverage depends on two structural conditions: the n=0 prohibition when R3=OH and a specific R2 exception when n=0, R1=methyl or ethyl, and R3=H.
- Claims 2 and 3 secure sub-genus protection for particular formula embodiments, including explicit n=0 / R3=H territory (Claim 2).
- Composition protection is broad (Claim 4) and dose-limited (Claim 5) to 10–500 mg active ingredient.
- Design-around is most clearly driven by the exception logic at n=0 plus the specific R1/R3 combination, and secondarily by controlling whether R3=OH is used.
FAQs
-
Does US 4,876,248 cover salts?
Yes. The claims include salts with inorganic or organic bases when R1 = H.
-
Is n=0 allowed for all compounds?
Yes for R3=H, but no when R3=OH. Claim 1 states n cannot be 0 if R3 is OH.
-
What is the single most important carve-out in Claim 1?
When n=0, R1 is methyl or ethyl, and R3=H, R2 cannot be the specifically defined substituted phenyl group with Q in {halogen, nitro, CF3} and T in {methyl, ethyl, butyl}.
-
How do Claims 4 and 5 expand protection beyond the chemical entity?
Claim 4 adds pharmaceutical compositions using an active ingredient within formula (I). Claim 5 further limits those compositions to 10–500 mg active ingredient.
-
If a competitor active fits the Claim 1 genus, is the case automatically strong?
The strongest overlap is when the competitor also fits the carve-out conditions (or avoids them) and when the product dosage and active form align with Claim 4/5 and the salt coverage rules.
References
[1] U.S. Patent 4,876,248, “methylene-diphosphonic acid compounds” (claims provided in prompt).
